ICER Episodes
Oct. 5, 2023
ICER’s Faux Updates
John O’Brien, President and CEO of the National Pharmaceutical Council, weighs in on ICER’s latest update that we are calling a “faux update”; The American Enterprise Institute has released its perspective on last year’s Inflation Reduction...
None
Sept. 28, 2023
QALY Update
Bill Smith, Director of the Life Sciences Initiative at the Pioneer Institute, dives into the so-called update to ICER’s value assessment framework; Congresswoman Cathy McMorris Rodgers explained earlier this year why she was against the QALY...
None
July 27, 2023
Biosimilars Reshape the Market
Avalere releases a study focused on ICER assessments and whether or not they take into account the patient experience when creating their reports; Wayne Winegarden, a Senior Fellow with the Pacific Research Institute explains how new Humira...
None
April 27, 2023
Liver Disease Patients at ICER, Healthcare Congressional Focus
Donna Cryer, CEO of the Global Liver Institute, previews liver disease patient advocates’ testimonies ahead of an ICER meeting on two new treatments; the House Health, Employment, Labor and Pensions Subcommittee holds a hearing titled Reducing...
None